Patents by Inventor Sooyoun Jun

Sooyoun Jun has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10077468
    Abstract: The present invention relates to a PCR primer facilitating hot-start PCR by suppressing non-specific amplification at room temperature and at the same time capable of reducing significantly non-specific amplification by dominating the amplification of the PCR product rather than the amplification of the original template from the third PCR cycle, more precisely a PCR primer prepared by additionally inserting the reverse-complementary sequence to a certain region starting from the 5?-start site of the 5?-terminus of the original primer which is composed of priming sequence to anneal to a PCR template into the 5?-terminus of the original primer and a PCR method using the same.
    Type: Grant
    Filed: August 12, 2008
    Date of Patent: September 18, 2018
    Assignee: iNtRON Biotechnology, Inc.
    Inventors: Seongjun Yoon, Hyunyoung Lee, Jinseok Yu, Sooyoun Jun, Sanghyeon Kang
  • Patent number: 9540616
    Abstract: The present invention relates to a composition comprising bacteriophage SP-1, the bacteriophage capable of destroying Salmonella once being infected in Salmonella, as an active ingredient, and a method for prevention and treatment of Salmonella infection using the same. Bacteriophage SP-1, the active ingredient of the composition of the present invention, characteristically has the killing activity to Salmonella and has the genome represented by SEQ. ID. NO: 1.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: January 10, 2017
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seong Jun Yoon, Sooyoun Jun, Hyoungrok Paik, Gimo Jung, Yoonsik Shin, Sanghyeon Kang
  • Publication number: 20160053234
    Abstract: The present invention relates to a composition comprising bacteriophage SP-1, the bacteriophage capable of destroying Salmonella once being infected in Salmonella, as an active ingredient, and a method for prevention and treatment of Salmonella infection using the same. Bacteriophage SP-1, the active ingredient of the composition of the present invention, characteristically has the killing activity to Salmonella and has the genome represented by SEQ. ID. NO: 1.
    Type: Application
    Filed: November 6, 2015
    Publication date: February 25, 2016
    Inventors: Seong Jun Yoon, Sooyoun Jun, Hyoungrok Paik, Gimo Jung, Yoonsik Shin, Sanghyeon Kang
  • Patent number: 9211309
    Abstract: The present invention relates to a composition comprising EK99P-1, a bacteriophage isolated from nature and capable of infecting E. coli type K99 so as to kill the same, as an active ingredient, and a method for preventing and treating E. coli type K99 infections using the said composition. According to the present invention, the bacteriophage EK99P-1, an active ingredient of the composition, has a killing activity against E. coli type K99 and has the genome represented by SEQ. ID. NO: 1.
    Type: Grant
    Filed: June 26, 2014
    Date of Patent: December 15, 2015
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seongjun Yoon, Sooyoun Jun, Hyoungrok Paik, Jeesoo Son, Sanghyeon Kang
  • Patent number: 9121023
    Abstract: The present invention relates to a PCR product cloning vector applicable directly to the cloning of a PCR product. More precisely, the present invention relates to a PCR product cloning vector designed to be effective in use for blue/white colony selection and produced based on the restriction enzyme treatment process to generate non-complementary unpaired single overhang and a method for producing the same. According to the method of the present invention, the PCR product cloning vector designed to be advantageous for blue/white cloning selection can be produced with improved efficiency compared with the convention method.
    Type: Grant
    Filed: October 29, 2008
    Date of Patent: September 1, 2015
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seongjun Yoon, SooYoun Jun, SangHyeon Kang
  • Patent number: 8951757
    Abstract: The present invention relates to a method for the preparation of a labeling agent derived from one type of tRNA prepared by in vitro transcription, which is usable for non-radioactive selective labeling of target proteins produced by in vitro translation with fluorophore or biotin; and a method for selective labeling of target proteins produced by in vitro translation using the labeling agent without labeling pre-existing proteins in the reaction mixture.
    Type: Grant
    Filed: January 7, 2009
    Date of Patent: February 10, 2015
    Assignee: Intron Biotechnology, Inc.
    Inventors: Seongjun Yoon, SooYoun Jun, SangHyeon Kang
  • Publication number: 20150004141
    Abstract: The present invention relates to a composition comprising EK99P-1, a bacteriophage isolated from nature and capable of infecting E. coli type K99 so as to kill the same, as an active ingredient, and a method for preventing and treating E. coli type K99 infections using the said composition. According to the present invention, the bacteriophage EK99P-1, an active ingredient of the composition, has a killing activity against E. coli type K99 and has the genome represented by SEQ. ID. NO: 1.
    Type: Application
    Filed: June 26, 2014
    Publication date: January 1, 2015
    Inventors: Seongjun YOON, Sooyoun JUN, Hyoungrok PAIK, Jeesoo SON, Sanghyeon KANG
  • Publication number: 20130273635
    Abstract: The present invention relates to a bacteriophage PA1? belonging to family Siphoviridae, characterized that it is capable of killing one or more bacteria strains selected from a group comprising Pseudomonas aeruginosa, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus homonis, Shigella sonnei, Listeria monocytogenes and Streptococcus pneumonia, and contains a full-length genome of SEQ ID NO: 1. According to the present invention, the bacteriophage PA1? can be used to kill said bacteria and reduce the same effectively. Also, it can be used to remove biofilms generated by said bacteria. Especially, this bacteriophage is applicable for medical industry, food industry, biotechnology and the like, because it is a sort of virus that kills host bacteria without any adverse effect on human, animals and so on. In addition, this bacteriophage can kill noxious bacteria on target sites or target supports without any problem related with resistance development of bacteria.
    Type: Application
    Filed: April 12, 2012
    Publication date: October 17, 2013
    Applicant: INTRON BIOTECHNOLOGY, INC.
    Inventors: Jung Min Kim, Shuk Ho Kim, Seongjun Yoon, Sooyoun Jun, Sanghyeon Kang
  • Patent number: 8377866
    Abstract: The present invention relates to a novel antimicrobial protein derived from bacteriophage having killing activity specific to Staphylococcus aureus, more precisely an antimicrobial protein originated from Podoviridae bacteriophage having killing activity specific to Staphylococcus aureus which is the causing agent of infectious disease in human and animals, a pharmaceutical composition for the prevention and treatment of infectious disease caused by Staphylococcus aureus, an antibiotic and a disinfectant containing the bacteriophage-originated antimicrobial protein as an active ingredient.
    Type: Grant
    Filed: February 12, 2009
    Date of Patent: February 19, 2013
    Assignee: Intron Biotechnology, Inc.
    Inventors: Seongjun Yoon, Yunjaie Choi, Seyung Lee, Jeesoo Son, Sooyoun Jun, Sanghyeon Kang
  • Patent number: 8377431
    Abstract: The present invention relates to compositions for removing a biofilm formed by Staphylococcus aureus, comprising a bacteriophage, such as Myoviridae family T4-like phage genus bacteriophage (Accession No: KCTC 11153BP, SAP-1) or Podoviridae family ?29-like virus genus bacteriophage (Accession No: KCTC11154BP, SAP-2), and lytic protein derived therefrom, that destroys the biofilm. Also disclosed are pharmaceutical compositions for the treatment of diseases caused by Staphylococcus aureus capable of forming biofilm.
    Type: Grant
    Filed: September 12, 2008
    Date of Patent: February 19, 2013
    Assignee: iNtRON Biotechnology, Inc.
    Inventors: Seongjun Yoon, Yunjaie Choi, Se Yung Lee, Jeesoo Son, Sooyoun Jun, Sanghyeon Kang
  • Publication number: 20130011369
    Abstract: The present invention relates to a composition comprising bacteriophage SP-1, the bacteriophage capable of destroying Salmonella once being infected in Salmonella, as an active ingredient, and a method for prevention and treatment of Salmonella infection using the same. Bacteriophage SP-1, the active ingredient of the composition of the present invention, characteristically has the killing activity to Salmonella and has the genome represented by SEQ. ID. NO: 1.
    Type: Application
    Filed: July 5, 2011
    Publication date: January 10, 2013
    Applicant: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seongjun Yoon, Sooyoun Jun, Hyoungrok Paik, Gimo Jung, Yoonsik Shin, Sanghyeon Kang
  • Patent number: 8329165
    Abstract: The present invention relates to a composition for the treatment of ballast water containing bacteriophage capable of killing specific target bacteria as an active ingredient in order to eliminate or reduce bacteria including pathogenic bacteria present in ballast water, and a biological treatment method of ballast water.
    Type: Grant
    Filed: September 5, 2008
    Date of Patent: December 11, 2012
    Assignee: Intron Biotechnology, Inc.
    Inventors: Seongjun Yoon, Sooyoun Jun, Sanghyeon Kang, Yunjaie Choi, Jeesoo Son
  • Patent number: 8066990
    Abstract: The present invention relates to a lysin protein originated from bacteriophage, more precisely a lysin protein comprising the amino acid sequence represented by SEQ. ID. NO: 2 which has no harm to human and animals comprising eukaryotic cells owing to its specificity to bacteria and has broad antibacterial activity, and a pharmaceutical composition for the prevention and treatment of infectious disease caused by bacteria comprising the said lysin protein as an active ingredient.
    Type: Grant
    Filed: April 14, 2009
    Date of Patent: November 29, 2011
    Assignee: Intron Biotechnology, Inc.
    Inventors: Seongjun Yoon, Yunjaie Choi, Jeesoo Son, Sooyoun Jun, Hyoungrok Paik, Sanghyeon Kang
  • Patent number: 8043613
    Abstract: The present invention relates to a novel bacteriophage, more precisely a Podoviridae bacteriophage having killing activity specific to Staphylococcus aureus which is the causing agent of infectious disease in human and animals, a pharmaceutical composition for the prevention and treatment of the disease caused by Staphylococcus aureus, an antibiotic and a disinfectant containing the bacteriophage as an active ingredient.
    Type: Grant
    Filed: February 12, 2009
    Date of Patent: October 25, 2011
    Assignee: iNtRON Biotechnology, Inc.
    Inventors: Seongjun Yoon, Yunjaie Choi, Seyung Lee, Jeesoo Son, Sooyoun Jun, Sanghyeon Kang
  • Publication number: 20110014714
    Abstract: The present invention relates to a method for the preparation of a labeling material (labeling agent) usable for non-radioactive selective labeling of proteins produced by in vitro translation with fluorophore or biotin; and a method for selective labeling of proteins produced by in vitro translation using the said labeling material. More specifically, the present invention provides a method for preparing a labeling material usable for selective labeling of a target protein produced only from the gene added to the cell-free protein synthesis reaction mixture by an experimenter without labeling pre-existing proteins in the reaction mixture, for which only one type of tRNA prepared by in vitro transcription is used instead of “total tRNA mixture”. The present invention also provides a method for labeling of the protein produced by in vitro translation by using the labeling material prepared by the above method.
    Type: Application
    Filed: January 7, 2009
    Publication date: January 20, 2011
    Applicant: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seongjun Yoon, SooYoun Jun, SangHyeon Kang
  • Publication number: 20100255570
    Abstract: The present invention relates to a PCR product cloning vector applicable directly to the cloning of a PCR product. More precisely, the present invention relates to a PCR product cloning vector designed to be effective in use for blue/white colony selection and produced based on the restriction enzyme treatment process to generate non- complementary unpaired single overhang and a method for producing the same. According to the method of the present invention, the PCR product cloning vector designed to be advantageous for blue/white cloning selection can be produced with improved efficiency compared with the convention method.
    Type: Application
    Filed: October 29, 2008
    Publication date: October 7, 2010
    Applicant: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seongjun Yoon, SooYoun Jun, SangHyeon Kang
  • Publication number: 20100254950
    Abstract: The present invention relates to compositions for removing a biofilm formed by Staphylococcus aureus, comprising a bacteriophage, such as Myoviridae family T4-like phage genus bacteriophage (Accession No: KCTC 11153BP, SAP-I) or Podoviridae family ?29-like virus genus bacteriophage (Accession No: KCTC11154BP, SAP-2), and lytic protein derived therefrom, that destroys the biofilm. Also disclosed are pharmaceutical compositions for the treatment of diseases caused by Staphylococcus aureus capable of forming biofilm.
    Type: Application
    Filed: September 12, 2008
    Publication date: October 7, 2010
    Inventors: Seongjun Yoon, Yunjaie Choi, Se Yung Lee, Jeesoo Son, Sooyoun Jun, Sanghyeon Kang
  • Publication number: 20100203180
    Abstract: The present invention relates to a novel antimicrobial protein derived from bacteriophage having killing activity specific to Staphylococcus aureus, more precisely an antimicrobial protein originated from Podoviridae bacteriophage having killing activity specific to Staphylococcus aureus which is the causing agent of infectious disease in human and animals, a pharmaceutical composition for the prevention and treatment of infectious disease caused by Staphylococcus aureus, an antibiotic and a disinfectant containing the bacteriophage-originated antimicrobial protein as an active ingredient.
    Type: Application
    Filed: February 12, 2009
    Publication date: August 12, 2010
    Applicant: iNtRon Biotechnology, Inc.
    Inventors: Seongjun Yoon, Yunjaie Choi, Seyung Lee, Jeesoo Son, Sooyoun Jun, Sanghyeon Kang
  • Publication number: 20100203019
    Abstract: The present invention relates to a novel bacteriophage, more precisely a Podoviridae bacteriophage having killing activity specific to Staphylococcus aureus which is the causing agent of infectious disease in human and animals, a pharmaceutical composition for the prevention and treatment of the disease caused by Staphylococcus aureus, an antibiotic and a disinfectant containing the bacteriophage as an active ingredient.
    Type: Application
    Filed: February 12, 2009
    Publication date: August 12, 2010
    Applicant: iNtRON Biotechnology, Inc.
    Inventors: Seongjun Yoon, Yunjaie Choi, Seyung Lee, Jeesoo Son, Sooyoun Jun, Sanghyeon Kang
  • Publication number: 20100172918
    Abstract: The present invention relates to a lysin protein originated from bacteriophage, more precisely a lysin protein comprising the amino acid sequence represented by SEQ. ID. NO: 2 which has no harm to human and animals comprising eukaryotic cells owing to its specificity to bacteria and has broad antibacterial activity, and a pharmaceutical composition for the prevention and treatment of infectious disease caused by bacteria comprising the said lysin protein as an active ingredient.
    Type: Application
    Filed: April 14, 2009
    Publication date: July 8, 2010
    Applicant: iNtRON Biotechnology, Inc.
    Inventors: SEONGJUN YOON, YUNJAIE CHOI, JEESOO SON, SOOYOUN JUN, HYOUNGROK PAIK, SANGHYEON KANG